NexImmune Announces Pricing of Upsized Initial Public Offering
GAITHERSBURG, Md., Feb. 11, 2021 (GLOBE NEWSWIRE) -- NexImmune, Inc., a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to employ the body’s own T cells to generate a specific, potent and durable immune response that mimics natural biology, today announced the pricing of its upsized initial public offering of 6,471,000 shares of its common stock at a price to the public of...